[
  {
    "ts": null,
    "headline": "Top S&P500 movers in Friday's session",
    "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.",
    "url": "https://finnhub.io/api/news?id=e949128c1a554c67a72000917615d4af2652de36980c1eec7865a1bb6bba1f45",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771013110,
      "headline": "Top S&P500 movers in Friday's session",
      "id": 139088340,
      "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
      "related": "VRTX",
      "source": "ChartMill",
      "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.",
      "url": "https://finnhub.io/api/news?id=e949128c1a554c67a72000917615d4af2652de36980c1eec7865a1bb6bba1f45"
    }
  },
  {
    "ts": null,
    "headline": "Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)",
    "summary": "A sales partner offered a ray of hope that this company couldn't for itself.",
    "url": "https://finnhub.io/api/news?id=7bdaa2d648e3e2b933f2dc5068d3bafbdfd104353b31565cf867662c90b0538e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771010571,
      "headline": "Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)",
      "id": 139088116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "A sales partner offered a ray of hope that this company couldn't for itself.",
      "url": "https://finnhub.io/api/news?id=7bdaa2d648e3e2b933f2dc5068d3bafbdfd104353b31565cf867662c90b0538e"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says",
    "summary": "Vertex Pharmaceuticals' (VRTX) Q4 was \"somewhat anticlimactic\" from a pipeline perspective, but soli",
    "url": "https://finnhub.io/api/news?id=07ca83e3e5cd87ecdc14db366ce790b30462f581d84230a3f361bb80bd466451",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771004470,
      "headline": "Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says",
      "id": 139086655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals' (VRTX) Q4 was \"somewhat anticlimactic\" from a pipeline perspective, but soli",
      "url": "https://finnhub.io/api/news?id=07ca83e3e5cd87ecdc14db366ce790b30462f581d84230a3f361bb80bd466451"
    }
  },
  {
    "ts": null,
    "headline": "Friday's session: top gainers and losers in the S&P500 index",
    "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.",
    "url": "https://finnhub.io/api/news?id=a6d5fbb65e7b62b55258f7d99ecaac863967df635c2e772fcb62bacc5dbfaf72",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771004109,
      "headline": "Friday's session: top gainers and losers in the S&P500 index",
      "id": 139086377,
      "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
      "related": "VRTX",
      "source": "ChartMill",
      "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.",
      "url": "https://finnhub.io/api/news?id=a6d5fbb65e7b62b55258f7d99ecaac863967df635c2e772fcb62bacc5dbfaf72"
    }
  },
  {
    "ts": null,
    "headline": "VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales",
    "summary": "Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.",
    "url": "https://finnhub.io/api/news?id=84d695c27eec69c7698e13ba38005838d83f2b98a39c3f0e7122dbd829d33401",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771001580,
      "headline": "VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales",
      "id": 139086656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.",
      "url": "https://finnhub.io/api/news?id=84d695c27eec69c7698e13ba38005838d83f2b98a39c3f0e7122dbd829d33401"
    }
  },
  {
    "ts": null,
    "headline": "Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $558",
    "summary": "Scotiabank  analyst Greg Harrison   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and raises the price target from $495 to $558.",
    "url": "https://finnhub.io/api/news?id=7eaf41c02222ca386b7f15d28ec46f2a9f8b0b3e298646936ccaf42aa16f7498",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770996002,
      "headline": "Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $558",
      "id": 139095928,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "Scotiabank  analyst Greg Harrison   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and raises the price target from $495 to $558.",
      "url": "https://finnhub.io/api/news?id=7eaf41c02222ca386b7f15d28ec46f2a9f8b0b3e298646936ccaf42aa16f7498"
    }
  },
  {
    "ts": null,
    "headline": "CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates",
    "summary": "CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.",
    "url": "https://finnhub.io/api/news?id=aa098cd32ec9a6f2c32e2cdb6dd3f6542948765550e4c5b92ed17d41d5b900a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770995040,
      "headline": "CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates",
      "id": 139086657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.",
      "url": "https://finnhub.io/api/news?id=aa098cd32ec9a6f2c32e2cdb6dd3f6542948765550e4c5b92ed17d41d5b900a6"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow […]",
    "url": "https://finnhub.io/api/news?id=453c8d1d7080f0940c0d931a3248a3567a582aaa24060b150c94fdbaf3110bf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994493,
      "headline": "Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays",
      "id": 139085144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow […]",
      "url": "https://finnhub.io/api/news?id=453c8d1d7080f0940c0d931a3248a3567a582aaa24060b150c94fdbaf3110bf5"
    }
  },
  {
    "ts": null,
    "headline": "Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?",
    "summary": "After Thursday&#39;s broad-based tech selloff, Wall Street staged a rebound as a softer-than-expected inflation print reinforced expectations for interest-rate cuts during the year.",
    "url": "https://finnhub.io/api/news?id=c6704b4bd9dc180539b1d0d09aeeb565592b13c81183554675bbfe80fcbac388",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994125,
      "headline": "Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?",
      "id": 139095442,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/13/Concept-Of-Small-Cap-Write-On-Sticky-Not.jpeg?width=2048&height=1536",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "After Thursday&#39;s broad-based tech selloff, Wall Street staged a rebound as a softer-than-expected inflation print reinforced expectations for interest-rate cuts during the year.",
      "url": "https://finnhub.io/api/news?id=c6704b4bd9dc180539b1d0d09aeeb565592b13c81183554675bbfe80fcbac388"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens",
    "summary": "CRISPR Therapeutics highlights progress in clinical trials &amp; uptake of Casgevy gene therapy. Pipeline also advancing with promising data.",
    "url": "https://finnhub.io/api/news?id=73dc463cfd8f50b930bf3bcbaffd0c4ed0b9ca577b983f315833344df21c9bab",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770993949,
      "headline": "CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens",
      "id": 139095930,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/13/Crispr-Therapeutics.jpeg?width=2048&height=1536",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "CRISPR Therapeutics highlights progress in clinical trials &amp; uptake of Casgevy gene therapy. Pipeline also advancing with promising data.",
      "url": "https://finnhub.io/api/news?id=73dc463cfd8f50b930bf3bcbaffd0c4ed0b9ca577b983f315833344df21c9bab"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $541",
    "summary": "RBC Capital  analyst Brian Abrahams   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $546 to $541.",
    "url": "https://finnhub.io/api/news?id=6169f2a04beb8c8807f10fbc73b5cb66d8f8ad7927a950f5cf874333cd85d5c4",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770990835,
      "headline": "RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $541",
      "id": 139095931,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "RBC Capital  analyst Brian Abrahams   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $546 to $541.",
      "url": "https://finnhub.io/api/news?id=6169f2a04beb8c8807f10fbc73b5cb66d8f8ad7927a950f5cf874333cd85d5c4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary",
    "summary": "Moby summary of Vertex Pharmaceuticals Incorporated's Q4 2025 earnings call",
    "url": "https://finnhub.io/api/news?id=c8bb58cb8cdb7381b65796b5cc8077b2a51242ffa99cbcd39c485236b2092232",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770989400,
      "headline": "Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary",
      "id": 139092655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Moby summary of Vertex Pharmaceuticals Incorporated's Q4 2025 earnings call",
      "url": "https://finnhub.io/api/news?id=c8bb58cb8cdb7381b65796b5cc8077b2a51242ffa99cbcd39c485236b2092232"
    }
  },
  {
    "ts": null,
    "headline": "Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $466",
    "summary": "Stifel  analyst Paul Matteis   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $445 to $466.",
    "url": "https://finnhub.io/api/news?id=6ac36c97af63d5e479fc95f6a65709a7f99e9add57c536b51718154f6c68c56e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770988618,
      "headline": "Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $466",
      "id": 139095932,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "Stifel  analyst Paul Matteis   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $445 to $466.",
      "url": "https://finnhub.io/api/news?id=6ac36c97af63d5e479fc95f6a65709a7f99e9add57c536b51718154f6c68c56e"
    }
  },
  {
    "ts": null,
    "headline": "Vertex’s CRISPR therapy rebounds in latest earnings",
    "summary": "Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.",
    "url": "https://finnhub.io/api/news?id=a9819bdb2dd6aa0010b602c61fb36b01b799191c535a721a9d4c5d1272077ff8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770987621,
      "headline": "Vertex’s CRISPR therapy rebounds in latest earnings",
      "id": 139089763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.",
      "url": "https://finnhub.io/api/news?id=a9819bdb2dd6aa0010b602c61fb36b01b799191c535a721a9d4c5d1272077ff8"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Moderna, Instacart, Rivian Automotive, DraftKings, Coinbase & more",
    "summary": "Here are some of the biggest movers in midday trading.",
    "url": "https://finnhub.io/api/news?id=eecc84f88376a879caba590388a99eeee0c807fb6f8e4df6feabcb32937d19dc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770986770,
      "headline": "Stocks making the biggest moves midday: Moderna, Instacart, Rivian Automotive, DraftKings, Coinbase & more",
      "id": 139086408,
      "image": "https://image.cnbcfm.com/api/v1/image/108179666-1753963608092-gettyimages-2219723511-s3___bgmp-arc_arc-feeds_generic-photos_to-arc_ryanmoderna4bi.jpeg?v=1771004067&w=1920&h=1080",
      "related": "VRTX",
      "source": "CNBC",
      "summary": "Here are some of the biggest movers in midday trading.",
      "url": "https://finnhub.io/api/news?id=eecc84f88376a879caba590388a99eeee0c807fb6f8e4df6feabcb32937d19dc"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 sales results. Also, Oppenheimer upgraded the stock from Perform to Outperform and announced a $540 price target.",
    "summary": "Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 sales results. Also, Oppenheimer upgraded the stock from Perform to Outperform and announced a $540 price target.",
    "url": "https://finnhub.io/api/news?id=4b21e22922eb9837953c226ffb2a49147a4914893adf33bbcdc35399646e4f54",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770985117,
      "headline": "Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 sales results. Also, Oppenheimer upgraded the stock from Perform to Outperform and announced a $540 price target.",
      "id": 139095933,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4b21e22922eb9837953c226ffb2a49147a4914893adf33bbcdc35399646e4f54"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer Upgrades Vertex Pharmaceuticals to Outperform, Announces $540 Price Target",
    "summary": "Oppenheimer  analyst Jay Olson   upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Perform to Outperform and announces $540 price target.",
    "url": "https://finnhub.io/api/news?id=890caee766f6d6df117cbffd1f2ac8fd0f4c8a39b9824d17ffaa8c22037c7ae0",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770980917,
      "headline": "Oppenheimer Upgrades Vertex Pharmaceuticals to Outperform, Announces $540 Price Target",
      "id": 139095934,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "Oppenheimer  analyst Jay Olson   upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Perform to Outperform and announces $540 price target.",
      "url": "https://finnhub.io/api/news?id=890caee766f6d6df117cbffd1f2ac8fd0f4c8a39b9824d17ffaa8c22037c7ae0"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential",
    "summary": "Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. Both updates relate to Vertex expanding its rare disease and autoimmune portfolio beyond cystic fibrosis. Vertex Pharmaceuticals, NasdaqGS:VRTX, is drawing fresh attention as it adds new rare disease and autoimmune assets alongside its established cystic...",
    "url": "https://finnhub.io/api/news?id=2912f48aceff5084ef6ba37247c12ee522725318582740bc920f0baf449989f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770974387,
      "headline": "Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential",
      "id": 139079188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. Both updates relate to Vertex expanding its rare disease and autoimmune portfolio beyond cystic fibrosis. Vertex Pharmaceuticals, NasdaqGS:VRTX, is drawing fresh attention as it adds new rare disease and autoimmune assets alongside its established cystic...",
      "url": "https://finnhub.io/api/news?id=2912f48aceff5084ef6ba37247c12ee522725318582740bc920f0baf449989f4"
    }
  },
  {
    "ts": null,
    "headline": "A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=06a77dae1f7d3c0f86853578c7fa433da75478becf5764599d25be1c43407238",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770969632,
      "headline": "A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts",
      "id": 139080539,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_3.jpg?width=2048&height=1536",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=06a77dae1f7d3c0f86853578c7fa433da75478becf5764599d25be1c43407238"
    }
  },
  {
    "ts": null,
    "headline": "HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $518",
    "summary": "HC Wainwright &amp; Co.  analyst Andrew S. Fein   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $478 to $518.",
    "url": "https://finnhub.io/api/news?id=59b1448ba2c0c8f0b6181e766e0d4b9d5699174d597c1dd499a3c92c9e813847",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770968813,
      "headline": "HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $518",
      "id": 139080540,
      "image": "",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "HC Wainwright &amp; Co.  analyst Andrew S. Fein   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $478 to $518.",
      "url": "https://finnhub.io/api/news?id=59b1448ba2c0c8f0b6181e766e0d4b9d5699174d597c1dd499a3c92c9e813847"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $5.03 per share was 2.3% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=57ffc96c847cd0bb3252c993764f1aebefceb33f0807534b1da05e54aabd3096",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770960726,
      "headline": "VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase",
      "id": 139088117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $5.03 per share was 2.3% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=57ffc96c847cd0bb3252c993764f1aebefceb33f0807534b1da05e54aabd3096"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
    "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.",
    "url": "https://finnhub.io/api/news?id=c55ec39e0c407752b0de0bbd4234b67c8d73ebca81ffefbd091ae680cfeab566",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770959106,
      "headline": "Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
      "id": 139078150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.",
      "url": "https://finnhub.io/api/news?id=c55ec39e0c407752b0de0bbd4234b67c8d73ebca81ffefbd091ae680cfeab566"
    }
  },
  {
    "ts": null,
    "headline": "Sana Biotechnology: A Small, Speculative Play",
    "summary": "Sana Biotechnology, Inc. focuses on SC451 for type 1 diabetes as single-patient data validates its immune-evasion platform. Check out why SANA stock is a buy.",
    "url": "https://finnhub.io/api/news?id=ba16626bf16148e35087825137bcb5229066cb7bef1c48e91a93e86392db6a18",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770953094,
      "headline": "Sana Biotechnology: A Small, Speculative Play",
      "id": 139078782,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283342789/image_1283342789.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Sana Biotechnology, Inc. focuses on SC451 for type 1 diabetes as single-patient data validates its immune-evasion platform. Check out why SANA stock is a buy.",
      "url": "https://finnhub.io/api/news?id=ba16626bf16148e35087825137bcb5229066cb7bef1c48e91a93e86392db6a18"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Q4 Earnings Call Highlights",
    "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF),",
    "url": "https://finnhub.io/api/news?id=8899f125339b2c72f408d0933b55713278703a32e1835e568808fbf33add3acc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770948448,
      "headline": "Vertex Pharmaceuticals Q4 Earnings Call Highlights",
      "id": 139077681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF),",
      "url": "https://finnhub.io/api/news?id=8899f125339b2c72f408d0933b55713278703a32e1835e568808fbf33add3acc"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated 2025 Q4 - Results - Earnings Call Presentation",
    "summary": "2026-02-13. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q4 earnings call.",
    "url": "https://finnhub.io/api/news?id=cedbbec8f0628b3e653dccaf43a32ee999881257b79ff6cb90e8117d502fb8ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770946746,
      "headline": "Vertex Pharmaceuticals Incorporated 2025 Q4 - Results - Earnings Call Presentation",
      "id": 139078322,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "2026-02-13. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q4 earnings call.",
      "url": "https://finnhub.io/api/news?id=cedbbec8f0628b3e653dccaf43a32ee999881257b79ff6cb90e8117d502fb8ac"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Stock Drops After Hours — Here's Why It's Trending Tonight",
    "summary": "Vertex Pharmaceuticals shares dipped 1.24% in after-hours trading Thursday despite reporting a 10% rise in fourth-quarter revenue to $3.19 billion.",
    "url": "https://finnhub.io/api/news?id=90cb6c183cd44be4d4c02c5b3af712f9b469f74f249ebc85d07f6fbd78cdc2b9",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770941667,
      "headline": "Vertex Pharmaceuticals (VRTX) Stock Drops After Hours — Here's Why It's Trending Tonight",
      "id": 139080541,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/12/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpeg?width=2048&height=1536",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": "Vertex Pharmaceuticals shares dipped 1.24% in after-hours trading Thursday despite reporting a 10% rise in fourth-quarter revenue to $3.19 billion.",
      "url": "https://finnhub.io/api/news?id=90cb6c183cd44be4d4c02c5b3af712f9b469f74f249ebc85d07f6fbd78cdc2b9"
    }
  }
]